The proposed model qualitatively and precisely predicts this behavior and we observed decreased proportions of all lymphocyte subsets including plasmacytoid cells in the CSF of natalizumab treated patients (Figure 4B, left), whereas a relative increase of differentiated CD4+ and CD8+ T cells was observed in the PB and CSF of RRMS patients treated with alemtuzumab (Figure 4 B, right). The gene discussed is CD4; the disease is relapsing-remitting multiple sclerosis.